BDNF Release Is Required for the Behavioral Actions of Ketamine

Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses

(2013) Bhavya Voleti et al.   BIOLOGICAL PSYCHIATRY

Synaptic Dysfunction in Depression: Potential Therapeutic Targets

(2012) R. S. Duman et al.   SCIENCE

Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex

(2011) Rong-Jian Liu et al.   BIOLOGICAL PSYCHIATRY

mTOR activation is required for the antidepressant effects of mGluR2/3 blockade

(2011) Jason M. Dwyer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

(2011) Anita E. Autry et al.   NATURE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression

(2009) Rebecca B. Price et al.   BIOLOGICAL PSYCHIATRY

L-Type Voltage-Dependent Calcium Channel Antagonists Impair Perirhinal Long-Term Recognition Memory and Plasticity Processes

(2009) A. Seoane et al.   JOURNAL OF NEUROSCIENCE

Positive AMPA Receptor Modulation Rapidly Stimulates BDNF Release and Increases Dendritic mRNA Translation

(2009) H. Jourdi et al.   JOURNAL OF NEUROSCIENCE

Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety

(2009) J M Gatt et al.   MOLECULAR PSYCHIATRY

BDNF Activates mTOR to Regulate GluR1 Expression Required for Memory Formation

(2009) Leandro Slipczuk et al.   PLoS One

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

(2007) Sungho Maeng et al.   BIOLOGICAL PSYCHIATRY